Advertisement

Archives of Gynecology and Obstetrics

, Volume 300, Issue 3, pp 717–724 | Cite as

Long-term oncologic outcome and its prognostic indicators in reproductive-age women with ovarian clear-cell carcinoma

  • Hiroaki KajiyamaEmail author
  • Shiro Suzuki
  • Nobuhisa Yoshikawa
  • Kaoru Niimi
  • Michiyasu Kawai
  • Kiyosumi Shibata
  • Fumitaka Kikkawa
Gynecologic Oncology
  • 60 Downloads

Abstract

Background

Clear-cell carcinoma (CCC) in reproductive-age women is likely to become an increasingly critical issue regarding possibilities of infertility, hormonal dysfunction, and mortality. The aim of this study was to examine the long-term oncologic outcome and its prognostic indicators based on a multicentric cohort of young patients with CCC.

Patients and methods

During the period of 1990–2015, a total of 164 patients aged 45-year-old or younger were enrolled in the study. Clinicopathologic data of these young patients with CCC collected under a centralized pathological review system were subjected to uni- and multivariable analyses to evaluate overall survival (OS).

Results

The median follow-up was 73.8 months (range 5.2–244.2) in the surviving patients. Among these patients, 104 (63.4%) had FIGO I disease, and 22 (13.4%), 31 (18.9%), and 7 (4.3%) had II, III, and IV disease, respectively. The 5-year OS rate was 74.5%. On stratification by the FIGO stage, the 5-year OS rates were as follows: stage I (90.2%), stage II (57.9%), and stage III/IV (39.3%), respectively (P < 0.0001). Confining analysis to stage I patients, there was no difference in OS between those who underwent fertility-sparing surgery and those who received radical surgery (P = 0.1593). In relapsed patients, the median survival after recurrence was 11.6 months. In multivariable analysis of stage I patients, the capsule status was an independent prognostic indicator of OS {IC2/IC3 vs. IA/IC1: HR 4.293 (95% CI 1.140–16.422), P = 0.0318}.

Conclusion

CCC patients staged greater than IC2/IC3 show a markedly increased risk of mortality. Thus, it is important to diagnose patients staged under IC2/IC3.

Keywords

Epithelial ovarian carcinoma Clear-cell carcinoma Reproductive-age Fertility-sparing surgery Overall survival Post-recurrence survival 

Abbreviations

CCC

Clear-cell carcinoma

FSS

Fertility-sparing surgery

OS

Overall survival

PRS

Post-recurrence survival

Notes

Acknowledgements

We sincerely thank TOTSG members for collaborating in data collection.

Author contributions

HK: data analysis and interpretation, drafting paper; SS, NY, KN, MK: data collection; KS: revising manuscript; FK: supervising and funding.

Compliance with ethical standards

Conflict of interest

All authors declare that there are no conflicts of interest.

References

  1. 1.
    Committee Japanese Gynecologic Cancer (2012) Annual report on Japanese gynecologic cancer committee. Acta Obstet Gynecol Jpn 64:1029–1141Google Scholar
  2. 2.
    Giudice LC, Kao LC (2004) Endometriosis. Lancet 364:1789–1799CrossRefGoogle Scholar
  3. 3.
    Mogensen JB, Kjaer SK, Mellemkjaer L, Jensen A (2016) Endometriosis and risks for ovarian, endometrial and breast cancers: a nationwide cohort study. Gynecol Oncol 143(1):87–92CrossRefGoogle Scholar
  4. 4.
    Kim HS, Kim TH, Chung HH, Song YS (2014) Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. Br J Cancer 110:1878–1890CrossRefGoogle Scholar
  5. 5.
    Gadducci A, Lanfredini N, Tana R (2014) Novel insights on the malignant transformation of endometriosis into ovarian carcinoma. Gynecol Endocrinol 30:612–617CrossRefGoogle Scholar
  6. 6.
    Zeppernick F, Meinhold-Heerlein I (2014) The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet 290:839–842CrossRefGoogle Scholar
  7. 7.
    Suzuki S, Kajiyama H, Shibata K, Ino K, Nawa A, Sakakibara K, Matsuzawa K, Takeda A, Kinoshita Y, Kawai M, Nagasaka T, Kikkawa F (2008) Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients? Ann Oncol 19:1284–1287CrossRefGoogle Scholar
  8. 8.
    Kajiyama H, Mizuno M, Shibata K, Umezu T, Suzuki S, Yamamoto E, Mitsui H, Sekiya R, Niimi K, Kawai M, Nagasaka T, Kikkawa F (2014) A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age. Int J Clin Oncol 19:921–927CrossRefGoogle Scholar
  9. 9.
    Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS (2008) Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 109:370–376CrossRefGoogle Scholar
  10. 10.
    Takano M, Sugiyama T, Yaegashi N, Sagae S, Kuzuya K, Udagawa Y, Tsuda H, Suzuki M, Kigawa J, Goto T, Tsuda H, Moriya T, Kikuchi Y (2010) Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer 20:1506–1510Google Scholar
  11. 11.
    Utsunomiya H, Akahira J, Tanno S, Moriya T, Toyoshima M, Niikura H, Ito K, Morimura Y, Watanabe Y, Yaegashi N (2006) Paclitaxel–platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Int J Gynecol Cancer 16:52–56CrossRefGoogle Scholar
  12. 12.
    Cabry R, Merviel P, Hazout A, Belloc S, Dalleac A, Copin H, Benkhalifa M (2014) Management of infertility in women over 40. Maturitas 78:17–21CrossRefGoogle Scholar
  13. 13.
    Kajiyama H, Shibata K, Mizuno M, Hosono S, Kawai M, Nagasaka T, Kikkawa F (2011) Fertility-sparing surgery in patients with clear-cell carcinoma of the ovary: is it possible? Hum Reprod 26:3297–3302CrossRefGoogle Scholar
  14. 14.
    Ferraretti AP, Goossens V, Kupka M, Bhattacharya S, de Mouzon J, Castilla JA, Erb K, Korsak V, Nyboe Andersen A, European IVFMCftESoHR Embryology (2013) Assisted Reproductive Technology in Europe, 2009: results generated from European registers by ESHRE. Hum Reprod 28:2318–2331CrossRefGoogle Scholar
  15. 15.
    Nyboe Andersen A, Gianaroli L, Nygren KG, European IVFmp, European Society of Human R (2004) Embryology assisted reproductive technology in Europe, 2000. Results generated from European registers by ESHRE. Hum Reprod 19:490–503CrossRefGoogle Scholar
  16. 16.
    Yamagami W, Aoki D (2015) Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology. J Obstet Gynaecol Res 41:1861–1869CrossRefGoogle Scholar
  17. 17.
    Fruscio R, Corso S, Ceppi L, Garavaglia D, Garbi A, Floriani I, Franchi D, Cantu MG, Bonazzi CM, Milani R, Mangioni C, Colombo N (2013) Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. Ann Oncol 24:138–144CrossRefGoogle Scholar
  18. 18.
    Kajiyama H, Shibata K, Suzuki S, Ino K, Nawa A, Kawai M, Nagasaka T, Kikkawa F (2010) Fertility-sparing surgery in young women with invasive epithelial ovarian cancer. Eur J Surg Oncol 36:404–408CrossRefGoogle Scholar
  19. 19.
    Morice P, Leblanc E, Rey A, Baron M, Querleu D, Blanchot J, Duvillard P, Lhomme C, Castaigne D, Classe JM, Bonnier P, GCCLCC, SFOG (2005) Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Societe Francaise d'Oncologie Gynecologique). Hum Reprod 20:1379–1385CrossRefGoogle Scholar
  20. 20.
    Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, Nam JH (2008) Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol 110:345–353CrossRefGoogle Scholar
  21. 21.
    Satoh T, Hatae M, Watanabe Y, Yaegashi N, Ishiko O, Kodama S, Yamaguchi S, Ochiai K, Takano M, Yokota H, Kawakami Y, Nishimura S, Ogishima D et al (2010) Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. J Clin Oncol 28:1727–1732CrossRefGoogle Scholar
  22. 22.
    Chan JK, Loizzi V, Lin YG, Osann K, Brewster WR, DiSaia PJ (2003) Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? Obstet Gynecol 102:156–161Google Scholar
  23. 23.
    Thigpen T, Brady MF, Omura GA, Creasman WT, McGuire WP, Hoskins WJ, Williams S (1993) Age as a prognostic factor in ovarian carcinoma: the Gynecologic Oncology Group experience. Cancer 71:606–614CrossRefGoogle Scholar
  24. 24.
    Takano M, Sugiyama T, Yaegashi N, Sakuma M, Suzuki M, Saga Y, Kuzuya K, Kigawa J, Shimada M, Tsuda H, Moriya T, Yoshizaki A, Kita T et al (2008) Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer 18:937–942CrossRefGoogle Scholar
  25. 25.
    Anglesio MS, Carey MS, Kobel M, Mackay H, Huntsman DG, Vancouver Ovarian Clear Cell Symposium S (2011) Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol 121:407–415CrossRefGoogle Scholar
  26. 26.
    Miyazawa M, Yasuda M, Fujita M, Kajiwara H, Hirabayashi K, Takekoshi S, Hirasawa T, Murakami M, Ogane N, Kiguchi K, Ishiwata I, Mikami M, Osamura RY (2009) Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol Int 59:19–27CrossRefGoogle Scholar
  27. 27.
    Rahman M, Nakayama K, Rahman MT, Nakayama N, Ishikawa M, Katagiri A, Iida K, Nakayama S, Otsuki Y, Shih IM, Miyazaki K (2012) Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Hum Pathol 43:2197–2206CrossRefGoogle Scholar
  28. 28.
    Kikuchi Y, Kudoh K, Talano M, Kikuchi R, Kita T, Hamada Y (2010) Effect of treatment by temsirolimus on patients with clear cell carcinoma of the ovary. J Clin Oncol 28(15):5086.  https://doi.org/10.1200/jco.2010.28.15_suppl.5086 (Abstract 5086)CrossRefGoogle Scholar
  29. 29.
    Disis ML, Patel MR, Pant S, Hamilton EP, Lockhart AC, Kelly K, Beck JT, Gordon MS, Weiss GJ, Taylor MH et al (2016) Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN solid tumor phase Ib trial: safety and clinical activity. J Clin Oncol 34(15):5533.  https://doi.org/10.1200/JCO.2016.34.15_suppl.5533 (suppl; abstr5533)CrossRefGoogle Scholar
  30. 30.
    Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T et al (2015) Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33:4015–4022CrossRefGoogle Scholar
  31. 31.
    Gaillard SL, Secord AA, Monk B (2016) The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract 3:11CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyNagoya University Graduate School of MedicineNagoyaJapan
  2. 2.Department of Obstetrics and GynecologyToyohashi Municipal HospitalAichiJapan
  3. 3.Department of Obstetrics and GynecologyBantane Hospital, Fujita Health UniversityAichiJapan

Personalised recommendations